Pilotstudy: Immunological effects of acupuncture

Not Applicable

• Conditions: M06; M05; Other rheumatoid arthritis; Seropositive rheumatoid arthritis

• Registration Number: DRKS00012623
• Lead Sponsor: Rheumatologie und Immunologie, Universitätsklinik für Innere Medizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-01-22
• Study Start: 2017-07-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Age: 20-65 years
Diagnosis: rheumatoid Arthritis (according to ACR/EULAR-criteria)
Duration of disease: 6 months to 10 years
Disease activity: low activity (CDAI 5-10)

Exclusion Criteria

Steroid-Therapy
Gravidity
Fever
neurological diseases
Infection in the past 14 days
planed or expected change in immunmodulating medication

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relative numbers of 28 negativ T-helper cells measured through fluorescence flow-cytometry (FACS). Probes are collected in week 0, 8 and 12. The final follow-up is in week 12.

Secondary Outcome Measures

Name	Time	Method
CD45+, CD19+, CD19+56, CD3+, CD4+, CD8+-cells, naive T-helper cells, Memory T-cells, regulatory T-helper cells (measured through FACS)<br>Cortisol-plasmalevel<br>disease activity (CDAI and DAS28 score according to EULAR/ACR criteria)<br>Follow-ups: Week 0, 8, and 12<br>Final follow-up: Week 12